SciELO - Scientific Electronic Library Online

vol.6 issue3Antidiabetics in Heart FailureQuality standards in the follow-up of elderly patients with heart failure and significant comorbidity. author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand



Related links


Revista Uruguaya de Medicina Interna

Print version ISSN 2393-6797On-line version ISSN 2393-6797


GRANA, Diego et al. Immunosuppressants in Systemic Sclerosis. Use and therapeutic response. Rev. Urug. Med. Int. [online]. 2021, vol.6, n.3, pp.22-30.  Epub Dec 01, 2021. ISSN 2393-6797.


Systemic sclerosis (SS) is a complex and heterogeneous disease. Its therapeutic approach and immunosuppression opportunity is not completely defined, it remains a challenge.


To describe the usage and therapeutic response to immunosuppressive agents (IS) in a cohort of patients with SS.


Patients with SS assisted in 2 units of systemic autoimmune diseases were selected. Those who received IS were included. Variables studied were sex, age and IS indication. Those with respiratory manifestations were assessed with functional lung tests previous and after treatment.


20 patients, 17 females. The mean age was 64 years old. The main indication of IS was respiratory manifestations followed by skin and articular symptoms. Induction treatment was indicated in 75% of respiratory patients vs. 12% in those with other manifestations. Mycophenolate mofetil was the most widely immunosuppressive agent employed.


The main prescription of IS in SS was for patients with respiratory manifestations. An increased use of MMF among other IS was observed as well as a favourable response in lung function tests in patients treated with IS.

Keywords : treatment; systemic sclerosis; immunosuppression.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )